USA-based Lpath (Nasdaq: LPTN) says that its multicenter, Phase II "Nexus" clinical trial evaluating iSONEP in patients with wet age-related macular degeneration (wet-AMD) did not meet its primary or key secondary endpoints. The company’s shares nose-dived in pre-market trading this morning, falling 73.8% to $0.45.
Wet AMD patients who had not responded adequately to existing anti-vascular endothelial growth factor (VEGF) therapies including Lucentis (ranibizumab), Avastin bevacizumab) and Eylea (aflibercept) did not show any statistically-significant improvement in visual acuity when treated with iSONEP as an adjunctive or monotherapy.
This is the second disappointment for Lpath in the last couple of months, when the company’ announced that its investigational therapy Asonep (sonepcizumab) did not meet the primary endpoint in a Phase IIa trial in renal cell carcinoma (The Pharma Letter March 25).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze